Research programme: immunotherapeutic vaccines - Aastrom/Stanford University

Drug Profile

Research programme: immunotherapeutic vaccines - Aastrom/Stanford University

Alternative Names: CIK therapy - Aastrom/Stanford University; Cytokine induced killer cell therapy - Aastrom/Stanford University; Dendricell

Latest Information Update: 18 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aastrom Biosciences; Stanford University
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Epstein-Barr virus infections; Hodgkin's disease; Multiple myeloma

Most Recent Events

  • 18 May 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 18 May 2006 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route)
  • 18 May 2006 Discontinued - Preclinical for Epstein-Barr virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top